Brain targeting of risperidone-loaded solid lipid nanoparticles by intranasal route

Journal of Drug Targeting

Volumn 19, Issue 6, 2011, Pages 468-474

  Patel, Sonal ^a   Chavhan, Sandip ^a   Soni, Heena ^a   Babbar, A K ^b   Mathur, Rashi ^b   Mishra, A K ^b   Sawant, Krutika ^a  

^a M S UNIVERSITY OF BARODA   (India)

^b INSTITUTE OF NUCLEAR MEDICINE AND ALLIED SCIENCES   (India)

Author keywords

biodistribution; Brain targeting; intranasal; risperidone; solid lipid nanoparticles

Indexed keywords

POLY(METHYL METHACRYLATE); RISPERIDONE; SOLID LIPID NANOPARTICLE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG HALF LIFE; DRUG RELEASE; DRUG STABILITY; DRUG TARGETING; EMULSION; EVAPORATION; FEMALE; GAMMA SCINTIGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; NOSE CAVITY; PARTICLE SIZE; PRIORITY JOURNAL; ZETA POTENTIAL;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; BLOOD-BRAIN BARRIER; BRAIN; DRUG CARRIERS; DRUG COMPOUNDING; FEMALE; INJECTIONS, INTRAVENOUS; LIPIDS; MALE; MICE; MICE, INBRED BALB C; NANOPARTICLES; PARTICLE SIZE; REACTION TIME; RISPERIDONE; SOLUBILITY; SURFACE PROPERTIES; TISSUE DISTRIBUTION;

EID: 79958807960     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2010.523787     Document Type: Article

References (31)

1. Banks WA, Morley JE, Niehoff ML, Mattern C. (2009). Delivery of testosterone to the brain by intranasal administration: comparison to intravenous testosterone. J Drug Target, 17, 91-97.
2. Blasi P, Giovagnoli S, Schoubben A, Ricci M, Rossi C. (2007). Solid lipid nanoparticles for targeted brain drug delivery. Adv Drug Deliv Rev, 59, 454-477. (Pubitemid 47259226)
3. Bondì ML, Fontana G, Carlisi B, Giammona G. (2003). Preparation and characterization of solid lipid nanoparticles containing cloricromene. Drug Deliv, 10, 245-250. (Pubitemid 37494138)
4. Chow HS, Chen Z, Matsuura GT. (1999). Direct transport of cocaine from the nasal cavity to the brain following intranasal cocaine administration in rats. J Pharm Sci, 88, 754-758. (Pubitemid 29398540)
5. Dhuria SV, Hanson LR, Frey WH, 2nd. (2010). Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci, 99, 1654-1673.
6. Doijad RC, Manvi FV, Godhwani DM, Joseph R, Deshmukh NV. (2008). Formulation and targeting efficiency of cisplatin engineered solid lipid nanoparticles. Indian J Pharm Sci, 70, 203-207. (Pubitemid 351920197)
7. Ellenbroek BA, Peeters BW, Honig WM, Cools AR. (1987). The paw test: a behavioural paradigm for differentiating between classical and atypical neuroleptic drugs. Psychopharmacology (Berl), 93, 343-348. (Pubitemid 17160658)
8. Ellenbroek BA, Zhang XX, Jin GZ. (2006). Effects of (-)stepholidine in animal models for schizophrenia. Acta Pharmacol Sin, 27, 1111-1118. (Pubitemid 44410990)
9. Huang G, Zhang N, Bi X, Dou M. (2008). Solid lipid nanoparticles of temozolomide: potential reduction of cardial and nephric toxicity. Int J Pharm, 355, 314-320.
10. http://www.drugs.com (Accessed on March 12, 2010). http://www.nlm.nih. gov/medlineplus/druginformation.html (Accessed on March 12, 2010).
11. Illum L. (2003). Nasal drug delivery-possibilities, problems and solutions. J Control Release, 87, 187-198. (Pubitemid 36255456)
12. Illum L. (2000). Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci, 11, 1-18. (Pubitemid 30410839)
13. Khan S, Patil K, Bobade N, Yeole P, Gaikwad R. (2010). Formulation of intranasal mucoadhesive temperature-mediated in situ gel containing ropinirole and evaluation of brain targeting efficiency in rats. J Drug Target, 18, 223-234.
14. Koziara JM, Lockman PR, Allen DD, Mumper RJ. (2003). In situ blood-brain barrier transport of nanoparticles. Pharm Res, 20, 1772-1778. (Pubitemid 37449450)
15. Kumar M, Misra A, Babbar AK, Mishra AK, Mishra P, Pathak K. (2008). Intranasal nanoemulsion based brain targeting drug delivery system of risperidone. Int J Pharm, 358, 285-291.
16. Lu W, Jiang W, Chen J, Yin M, Wang Z, Jiang X. (2008). Modulation of brain delivery and copulation by intranasal apomorphine hydrochloride. Int J Pharm, 349, 196-205. (Pubitemid 350299715)
17. Manjunath K, Venkateswarlu V. (2005). Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intradeodenal administration. J Control Release, 107, 215-228. (Pubitemid 41319672)
18. Mathison S, Nagilla R, Kompella UB. (1998). Nasal route for direct delivery of solutes to the central nervous system: fact or fiction? J Drug Target, 5, 415-441. (Pubitemid 28499678)
19. Mehnert W, Mäder K. (2001). Solid lipid nanoparticles: production, characterization and applications. Adv Drug Deliv Rev, 47, 165-196. (Pubitemid 32324113)
20. Mistry A, Stolnik S, Illum L. (2009). Nanoparticles for direct nose-tobrain delivery of drugs. Int J Pharm, 379, 146-157.
21. Müller RH, Mäder K, Gohla S. (2000). Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur J Pharm Biopharm, 50, 161-177. (Pubitemid 30326695)
22. Pietrowky R, Thieman A, Kern W, Fehm HL, Bern J. (1996). A nose-brain pathway for psychotropic peptides, evidence from a brain evolved potential study with cholecystokinin. Psychoneuroendocrinology, 21, 559-572. (Pubitemid 27061944)
23. Powell CM, Miyakawa T. (2006). Schizophrenia-relevant behavioral testing in rodent models: a uniquely human disorder? Biol Psychiatry, 59, 1198-1207.
24. Reger MA, Watson GS, Frey WH 2nd, Baker LD, Cholerton B, Keeling ML, Belongia DA, Fishel MA, Plymate SR, Schellenberg GD, Cherrier MM, Craft S. (2006). Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiol Aging, 27, 451-458. (Pubitemid 43185331)
25. Roland I, Piel G, Delattre L, Evrard B. (2003). Systematic characterization of oil-in-water emulsions for formulation design. Int J Pharm, 263, 85-94. (Pubitemid 37087935)
26. Saha GB. (1993a). Methods of radiolabeling. In: Physics and Radiobiology of Nuclear Medicine. Springer-Verlag, New York, pp. 100-106.
27. Saha GB. (1993b). Fundamentals of Nuclear Pharmacy, Quality control of Radiopharmaceuticals. Springer-Verlag, New York, pp. 154-160.
28. Souto EB, Mehnert W, Müller RH. (2006). Polymorphic behaviour of Compritol888 ATO as bulk lipid and as SLN and NLC. J Microencapsul, 23, 417-433. (Pubitemid 44132550)
29. Sussman N. (2002). Choosing an atypical antipsychotic. Int Clin Psychopharmacol, 17(Suppl. 3), S29-S33. (Pubitemid 35283712)
30. Wang JS, Ruan Y, Taylor RM, Donovan JL, Markowitz JS, DeVane CL. (2004). The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein. Int J Neuropsychopharmacol, 7, 415-419. (Pubitemid 39648071)
31. Yang SC, Lu LF, Cai Y, Zhu JB, Liang BW, Yang CZ. (1999). Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J Control Release, 59, 299-307. (Pubitemid 29238174)